MicroRNA-449a Inhibits Triple Negative Breast Cancer by Disturbing DNA Repair and Chromatid Separation
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MicroRNA-449a Inhibits Triple Negative Breast Cancer by Disturbing DNA Repair and Chromatid Separation
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 9, Pages 5131
Publisher
MDPI AG
Online
2022-05-05
DOI
10.3390/ijms23095131
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MicroRNA ‐192‐5p inhibits migration of triple negative breast cancer cells and directly regulates Rho GTPase activating protein 19
- (2021) Beate Vajen et al. GENES CHROMOSOMES & CANCER
- Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells
- (2018) Hélène Marijon et al. BIOMEDICINE & PHARMACOTHERAPY
- Identification of dysregulated miRNAs in triple negative breast cancer: A meta-analysis approach
- (2018) Leimarembi Devi Naorem et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4
- (2017) Maria Sandbothe et al. JOURNAL OF HEPATOLOGY
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- RAD52 Facilitates Mitotic DNA Synthesis Following Replication Stress
- (2016) Rahul Bhowmick et al. MOLECULAR CELL
- Survivin contributes to DNA repair by homologous recombination in breast cancer cells
- (2015) Eloïse Véquaud et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review
- (2015) Saira R. Ali et al. DRUG DEVELOPMENT RESEARCH
- MiR-34a Inhibits Viability and Invasion of Human Papillomavirus–Positive Cervical Cancer Cells by Targeting E2F3 and Regulating Survivin
- (2015) Dianzhong Geng et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Replication stress activates DNA repair synthesis in mitosis
- (2015) Sheroy Minocherhomji et al. NATURE
- The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
- (2015) Lao H Saal et al. Genome Medicine
- Roles of SLX1-SLX4, MUS81-EME1, and GEN1 in avoiding genome instability and mitotic catastrophe
- (2014) S. Sarbajna et al. GENES & DEVELOPMENT
- Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance
- (2014) Agnieszka Weinandy et al. NEOPLASIA
- Tumor-suppressive microRNA-449a induces growth arrest and senescence by targeting E2F3 in human lung cancer cells
- (2013) Xiao-Shuai Ren et al. CANCER LETTERS
- Genetic Susceptibility to Triple-Negative Breast Cancer
- (2013) K. N. Stevens et al. CANCER RESEARCH
- miR-449b inhibits the proliferation of SW1116 colon cancer stem cells through downregulation of CCND1 and E2F3 expression
- (2013) YANTIAN FANG et al. ONCOLOGY REPORTS
- Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells
- (2012) Reena Buurman et al. GASTROENTEROLOGY
- The relative efficiency of homology-directed repair has distinct effects on proper anaphase chromosome separation
- (2011) Corentin Laulier et al. NUCLEIC ACIDS RESEARCH
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started